| Similar Articles |
|---|
 |
Chemistry World
September 2, 2013
Emma Stoye |
Endo Health to buy Boca Pharmacal for $225m US speciality healthcare company Endo Health Solutions has agreed to buy Boca Pharmacal for $225 million in a bid to expand its generics business.   |
The Motley Fool
October 23, 2006
Brian Lawler |
Not the End for Endo An FDA decision won't hurt the maker of Lidoderm. Investors, take note. |
The Motley Fool
February 26, 2007
Brian Lawler |
Endo Brings in the Dough Why buy this pharmaceutical? Investors, let me count the ways. |
Job Journal
June 23, 2013 |
Jobwire Second sluggish month of California job creation... State's economy ramping up, but slowly... Optical manufacturer JDS Uniphase Corp is cutting 125 jobs... |
Chemistry World
October 23, 2013
Sarah Houlton |
Pharma manufacturing woes dog industry Many problems arise from quality control failures, according to Nicholson Price from Harvard Law School's Petrie-Flom center for health law policy, biotechnology and bioethics, this is not the only problem -- regulatory constraints can prevent process improvements being made. |
Chemistry World
October 10, 2014
Phillip Broadwith |
Endo outbids QLT for Auxilium merger US biotech Auxilium has backed out of a merger with Canadian firm QLT, in favor of a deal with US-based Endo. |
The Motley Fool
January 30, 2008
Brian Lawler |
The Endo a CEO Shares of Endo Pharmaceutical rise after its CEO, Peter Lankau, resigns. |
Pharmaceutical Executive
September 1, 2008 |
How Do You Solve a Problem Like Manufacturing? Outsourcing saves pharmaceutical companies money -- except when it doesn't. Here's how to decide what to do. |
The Motley Fool
January 10, 2007
Brian Lawler |
Endo's Plan to Bring In the Dough Despite little movement in the value of their shares, 2006 was an eventful year for investors in drug developer Endo Pharmaceuticals. |
The Motley Fool
April 30, 2007
Brian Lawler |
Nothing Wrong With Endo Endo Pharmaceuticals releases first-quarter financial results. Investors, take note. |
HBS Working Knowledge
March 14, 2005
Huselid, Becker, & Beatty |
Differentiating Your Workforce Strategy Even the best managers often forget to craft a workforce strategy along with their overall company strategy, but the two really need to be linked. An excerpt from the new book, The Workforce Scorecard. |
The Motley Fool
April 1, 2008
Brian Lawler |
The Endo a Patent? Endo sues to protect a lead drug from generic competition. |
The Motley Fool
March 20, 2007
Brian Lawler |
A Slowdown at Endo The FDA delays a decision on expanding the label for one of Endo's drugs. Investors, take note. |
The Motley Fool
March 15, 2011
Brian Orelli |
Extending the Competition in Parkinson's Disease Impax's extended-release drug looks good. |
IndustryWeek
September 1, 2006 |
Labor Days: Meeting Our Workforce Challenges! This special report takes the critical challenges facing U.S. manufacturers, puts them in perspective and presents the best workforce practices of America's plants. |
The Motley Fool
January 22, 2007
Brian Lawler |
The Feds Eye Endo Endo Pharmaceuticals' sales practices for Lidoderm prompt government scrutiny. Investors don't seem too concerned. |
BusinessWeek
March 14, 2005
Gene G. Marcial |
The Allure Of Impax "Impax' pipeline is impressive. So it's valuable as a stand-alone or as a buyout," says Robin Manners West of New Mexico's State Investment Council. |
IndustryWeek
March 1, 2008
David Blanchard |
Just In Time -- Buddy, Can You Spare a Job? U.S. manufacturers assert their continuing relevance despite a decline in overall employment and a lack of commitment from politicians. |
The Motley Fool
August 1, 2007
Brian Lawler |
Calling Out Endo Endo Pharmaceuticals gets taken to task by an activist investor. An investment group owning 5.6% of outstanding shares is concerned with how management plans to use $700 million available to them in cash and investments. |
The Motley Fool
April 12, 2011
Arundhati Parmar |
Endo Acquires Pelvic Care Firm American Medical Systems The company that began life in the pharmaceutical sector is venturing forth into devices in its quest to become more of a diversified health-care company. |
Food Processing
October 2010
Gerald Shankel |
America's Most Wanted: Skilled Workers A highly skilled and trained workforce is necessary to meet 21st century manufacturing needs. |
The Motley Fool
September 29, 2010
Brian Orelli |
A Mini-Teva in the Making Generic growth by Endo Pharmaceuticals. |
IndustryWeek
February 17, 2010
Jill Jusko |
IndustryWeek's 2010 Salary Survey Comments: Manufacturing Challenges in 2010 Your thoughts on what issues need to be addressed. |
The Motley Fool
November 6, 2007
Brian Lawler |
The Two Sides of Endo It has been a mixed third quarter for Endo Pharmaceuticals. On the financial side of things the company performed well; on the research and development side, things are not as good. |
Chemistry World
October 5, 2012
Phillip Broadwith |
Teva pulls generic antidepressant The move was prompted by an FDA investigation into whether the generic version (Budeprion XL, made by Impax and marketed by Teva) is truly therapeutically equivalent to the branded medicine (Wellbutrin XL). |
The Motley Fool
April 30, 2007
Brian Orelli |
No Pain for Endo's Investors Endo Pharmaceuticals had an impressive first quarter thanks to a new product and continued sales growth of its older brands. Investors, take note. |
BusinessWeek
December 11, 2006
Michael Arndt |
When A Winner Starts To Wane Endo is seeking to immunize itself from the slowing growth of its Lidoderm pain patch. |
National Defense
April 2008
Peter M. Steffes |
Sustaining Workforce is NDIA's Top Issue The National Defense Industrial Association identified the sustaining of the U.S. national security workforce advantage as its number one priority in 2008. |
The Motley Fool
February 25, 2008
Brian Lawler |
The Yin and Yang of Endo Endo Pharmaceuticals' fiscal 2007 report offered positive year-end financial results and a little bit of balance-sheet sourness. |
